4.7 Letter

Comment on: Redefining extended-spectrum β-lactamases: balancing science and clinical need

期刊

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
卷 64, 期 1, 页码 212-213

出版社

OXFORD UNIV PRESS
DOI: 10.1093/jac/dkp104

关键词

carbapenemases; cephalosporinases; ESBLs; nomenclature

向作者/读者索取更多资源

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Infectious Diseases

Outcomes of octogenarians and nonactogenarians with Pseudomonas aeruginosa bacteremia: a multicenter retrospective study

Alaa Atamna, Ili Margalit, Gida Ayada, Tanya Babich, Pontus Naucler, John Karlsson Valik, Christian G. Giske, Natividad Benito, Ruben Cardona, Alba Rivera, Celine Pulcini, Manal Abdel Fattah, Justine Haquin, Alasdair Macgowan, Bibiana Chazan, Anna Yanovskay, Ronen Ben Ami, Michal Landes, Lior Nesher, Adi Zaidman-Shimshovitz, Kate McCarthy, David L. Paterson, Evelina Tacconelli, Michael Buhl, Susanna Mauer, Jesus Rodriguez-Bano, Marina de Cueto, Antonio Oliver, Enrique Ruiz de Gopegui, Angela Cano, Isabel Machuca, Monica Gozalo-Marguello, Luis Martinez-Martinez, Eva M. Gonzalez-Barbera, Iris Gomez Alfaro, Miguel Salavert, Bojana Beovic, Andreja Saje, Manica Mueller-Premru, Leonardo Pagani, Virginie Vitrat, Diamantis Kofteridis, Maria Zacharioudaki, Sofia Maraki, Yulia Weissman, Mical Paul, Yaakov Dickstei, Dafna Yahav

Summary: This study aimed to evaluate outcomes of P. aeruginosa bacteremia among older adults (> 80 years) and found that disease severity, place of acquisition, and background conditions were associated with mortality, while antimicrobial regimen was not. Therefore, preventive efforts and early diagnosis might be beneficial for improving outcomes in older adults with P. aeruginosa bacteremia.

INFECTION (2023)

Review Infectious Diseases

The primary pharmacology of ceftazidime/avibactam: resistance in vitro

Wright W. Nichols, Sushmita D. Lahiri, Patricia A. Bradford, Gregory G. Stone

Summary: This article reviews the resistance to ceftazidime/avibactam and its primary pharmacology, which is thematically linked with recent reviews of the basic in vitro and in vivo translational biology of the combination (J Antimicrob Chemother 2022; 77: 2321-40 and 2341-52). Single-step exposures to 8x MIC of ceftazidime/avibactam resulted in frequencies of resistance in Enterobacterales or Pseudomonas aeruginosa.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Letter Infectious Diseases

Serum IFN-γ and RNAemia temporal profiles as biomarkers of severe COVID-19 in solid organ transplant and immunocompetent patients

Sonsoles Salto-Alejandre, Marta Carretero-Ledesma, Pedro Camacho-Martinez, Judith Berastegui-Cabrera, Carmen Infante, Regino Rodriguez-Alvarez, Jorge Alba, Patricia Perez-Palacios, Emilio Garcia-Diaz, Cristina Roca, Julia Praena, Maria Jose Blanco-Vidal, Sonia Santibanez, Rocio Valverde-Ortiz, Javier Nieto-Arana, Concepcion Garcia-Garcia, David Gutierrez-Campos, Natalia Maldonado, Gabriel Bernal, Miguel Angel Gomez-Bravo, Jose Manuel Sobrino, Manuela Aguilar-Guisado, Rocio Alvarez-Marin, Josune Goikoetxea-Aguirre, Jose Antonio Oteo, Zaira R. Palacios-Baena, Alvaro Pascual, Jose Antonio Lepe, Jesus Rodriguez-Bano, Jose Miguel Cisneros, Jeronimo Pachon, Javier Sanchez-Cespedes, Elisa Cordero

JOURNAL OF INFECTION (2023)

Letter Infectious Diseases

Impact of SARS-CoV-2 RNAemia and other risk factors on long-COVID: A prospective observational multicentre cohort study

Alexander Rombauts, Carmen Infante, Mikel del Alamo Martinez de Lagos, Jorge Alba, Adoracion Valiente, Carla Donado-Mazarron, Marta Carretero-Ledesma, Regino Rodriguez-Alvarez, Sonia Omatos, Zaira R. Palacios-Baena, Gabriela Abelenda-Alonso, Maria del Mar Silva-Sanchez, Ane Josune Goikoetxea-Agirre, Jose A. Oteo, Jesus Rodriguez-Bano, Elisa Cordero, Carlota Gudiol, Javier Sanchez-Cespedes, Jordi Carratala

JOURNAL OF INFECTION (2023)

Article Infectious Diseases

Effectiveness of fosfomycin trometamol as oral step-down therapy for bacteraemic urinary tract infections due to MDR Escherichia coli: a post hoc analysis of the FOREST randomized trial

Jesus Sojo-Dorado, Inmaculada Lopez-Hernandez, Alicia Hernandez-Torres, Pilar Retamar-Gentil, Esperanza Merino de Lucas, Laura Escola-Verge, Elena Bereciartua, Elisa Garcia-Vazquez, Vicente Pintado, Lucia Boix-Palop, Clara Natera-Kindelan, Luisa Sorli, Nuria Borrell, Concha Amador-Prous, Evelyn Shaw, Alfredo Jover-Saenz, Jose Molina, Rosa M. Martinez-Alvarez, Carlos J. Duenas, Jorge Calvo-Montes, Maria Lecuona, Virginia Pomar, Irene Borreguero, Virginia Palomo-Jimenez, Fernando Docobo-Perez, Alvaro Pascual, Jesus Rodriguez-Bano

Summary: This study compared the effectiveness and safety of fosfomycin trometamol and other oral drugs as step-down therapy for multidrug-resistant Escherichia coli (MDR-Ec) induced bacteremic urinary tract infections (BUTI). The results showed no significant difference in clinical and microbiological cure between fosfomycin trometamol and other drugs, but the relapse rate was higher in the fosfomycin trometamol group. Therefore, fosfomycin trometamol may be a reasonable option for step-down therapy in BUTI, but the relapse rate needs further evaluation.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Review Infectious Diseases

The primary pharmacology of ceftazidime/avibactam: microbiology from clinical studies, and development of resistance during treatment

Wright W. Nichols, Patricia A. Bradford, Gregory G. Stone

Summary: This article is a review of the microbiological findings in drug-exposed patients using the beta-lactam/beta-lactamase inhibitor combination ceftazidime/avibactam. Clinical trials showed that the microbiological response rates ranged from 58.8% to 86.1% depending on the susceptibility of the pathogens and the type of infection. Case studies also demonstrated comparable microbiological outcomes between ceftazidime/avibactam and other antibacterial treatments.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Article Medicine, General & Internal

Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers

Laure F. Pittet, Nicole L. Messina, Francesca Orsini, Cecilia L. Moore, Veronica Abruzzo, Simone Barry, Rhian Bonnici, Marc Bonten, John Campbell, Julio Croda, Margareth Dalcolmo, Kaya Gardiner, Grace Gell, Susie Germano, Adriano Gomes-Silva, Casey Goodall, Amanda Gwee, Tenaya Jamieson, Bruno Jardim, Tobias R. Kollmann, Marcus V. G. Lacerda, Katherine J. Lee, Michaela Lucas, David J. Lynn, Laurens Manning, Helen S. Marshall, Ellie McDonald, Craig F. Munns, Suellen Nicholson, Abby O'Connell, Roberto D. de Oliveira, Susan Perlen, Kirsten P. Perrett, Cristina Prat-Aymerich, Peter C. Richmond, Jesus Rodriguez-Bano, Glauce dos Santos, Patricia V. da Silva, Jia Wei Teo, Paola Villanueva, Adilia Warris, Nicholas J. Wood, Andrew Davidson, Nigel Curtis

Summary: In this international trial, healthcare workers were randomly assigned to receive either the BCG-Denmark vaccine or a saline placebo. After 6 months, it was found that the BCG vaccine did not reduce the risk of symptomatic or severe Covid-19 compared to placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Article Multidisciplinary Sciences

Efficacy and safety of different antimicrobial DURATions for the treatment of Infections associated with Osteosynthesis Material implanted after long bone fractures (DURATIOM): Protocol for a randomized, pragmatic trial

Carmen Garrigos, Clara Maria Rosso-Fernandez, Irene Borreguero, Patricia Rodriguez, Raquel Garcia-Albea, Jose Maria Bravo-Ferrer, Jesus Rodriguez-Bano, Maria Dolores del Toro

Summary: This study aims to investigate the optimal duration of antibiotic treatment in infection associated with osteosynthesis material (IOM) after long bone fractures. The hypothesis is that a shorter duration of antibiotic treatment can reduce antibiotic exposure, control antimicrobial resistance, and lower adverse events and costs, while still maintaining a high cure rate and functional recovery.

PLOS ONE (2023)

Review Public, Environmental & Occupational Health

Impact of COVID-19 pandemic on multidrug resistant gram positive and gram negative pathogens: A systematic review

Usman Abubakar, Menier Al-Anazi, Zainab Alanazi, Jesus Rodriguez-Bano

Summary: The COVID-19 pandemic has led to changes in the rate of multidrug resistant gram positive and gram negative bacteria. Studies have shown an increase in MRSA and VRE infection/colonization rates, while ESBL E. coli and ESBL Klebsiella pneumoniae rates have decreased. Overall, there has been an increase in the rate of multidrug resistant CRE infection/colonization during the pandemic, while the rate of CRPA infection has decreased.

JOURNAL OF INFECTION AND PUBLIC HEALTH (2023)

Article Microbiology

Phenotypic and Molecular Characterization of an Enterobacter ludwigii Clinical Isolate Carrying a Plasmid-Mediated blaIMI-6 Gene

T. Blanco-Martin, J. Guzman-Puche, C. Riazzo, M. Gasca-Santiyan, M. Hernandez-Garcia, R. Canton, J. Torre-Cisneros, C. Herrera, L. Martinez-Martinez

Summary: IMI carbapenemases confer an unusual resistance pattern, making them difficult to detect. Commercial molecular methods usually do not include bla(IMI) genes, contributing to the hidden dissemination of bacteria producing these enzymes. We report a plasmid-encoded IMI-6 carbapenemase in an Enterobacter ludwigii isolate, providing insights into its genetic characteristics.

MICROBIOLOGY SPECTRUM (2023)

Article Infectious Diseases

Heteroresistance to Colistin in Clinical Isolates of Klebsiella pneumoniae Producing OXA-48

Irene Sanchez-Leon, Teresa Garcia-Martinez, Seydina M. Diene, Elena Perez-Nadales, Luis Martinez-Martinez, Jean-Marc Rolain

Summary: This study aimed to investigate heteroresistance in nine clinical isolates of Klebsiella pneumoniae producing OXA-48 and describe genomic changes in vitro. It was found that the heteroresistance in K. pneumoniae isolates was mainly attributed to insertions in the mgrB gene and point mutations in colistin resistance proteins. These findings contribute to the understanding of colistin resistance mechanisms in OXA-48-producing K. pneumoniae mutants.

ANTIBIOTICS-BASEL (2023)

Article Critical Care Medicine

Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial

Marius Troseid, Jose R. Arribas, Lambert Assoumou, Aleksander Rygh Holten, Julien Poissy, Vida Terzic, Fulvia Mazzaferri, Jesus Rodriguez Bano, Joe Eustace, Maya Hites, Michael Joannidis, Jose-Artur Paiva, Jean Reuter, Isabel Puentmann, Thale D. J. H. Patrick-Brown, Elin Westerheim, Katerina Nezvalova-Henriksen, Lydie Beniguel, Tuva Borresdatter Dahl, Maude Bouscambert, Monika Halanova, Zoltan Peterfi, Sotirios Tsiodras, Michael Rezek, Matthias Briel, Serhat Unal, Martin Schlegel, Florence Ader, Karine Lacombe, Cecilie Delphin Amdal, Serge Rodrigues, Kristian Tonby, Alexandre Gaudet, Lars Heggelund, Joy Mootien, Asgeir Johannessen, Jannicke Horjen Moller, Beatriz Diaz Pollan, Anders Aune Tveita, Anders Benjamin Kildal, Jean-Christophe Richard, Olav Dalgard, Victoria Charlotte Simensen, Aliou Balde, Lucie de Gastines, Marta del Alamo, Burc Aydin, Fridtjof Lund-Johansen, Mary-Anne Trabaud, Alpha Diallo, Bente Halvorsen, John-Arne Rottingen, Evelina Tacconelli, Yazdan Yazdanpanah, Inge C. Olsen, Dominique Costagliola

Summary: The study conducted a placebo-controlled trial of baricitinib in severe/critical COVID cases. The results showed that baricitinib did not reduce mortality within 60 days, and there may be safety risks in vaccinated participants, which require further investigation.

CRITICAL CARE (2023)

Letter Infectious Diseases

Evaluation of RESIST ACINETO immunochromatographic assay from positive blood cultures

Nicla Giovacchini, Alberto Antonelli, Elia Taddei, Tommaso Giani, Gian Maria Rossolini

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Article Microbiology

Heteroresistance to colistin in wild-type Klebsiella pneumoniae isolates from clinical origin

Irene Sanchez-Leon, Elena Perez-Nadales, Juan Antonio Marin-Sanz, Teresa Garcia-Martinez, Luis Martinez-Martinez

Summary: This study investigated heteroresistance in 10 wild-type Klebsiella pneumoniae isolates of clinical origin. The results showed the importance of persistent variants and stable mutants in heteroresistance, and described the genomic changes observed in mutants obtained in population analysis profiling (PAP) assays.

MICROBIOLOGY SPECTRUM (2023)

Article Urology & Nephrology

Tunneled catheter-related bacteremia in hemodialysis patients: incidence, risk factors and outcomes. A 14-year observational study

Marina Almenara-Tejederas, Maria A. Rodriguez-Perez, Maria J. Moyano-Franco, Marina De Cueto-Lopez, Jesus Rodriguez-Bano, Mercedes Salgueira-Lazo

Summary: This retrospective study analyzed 406 tunneled catheters implanted in 325 patients over a period of 14 years to evaluate the incidence of tunneled catheter-related bacteremia and identify potential factors associated with the first episode of bacteremia. The results showed a low incidence rate of bacteremia, which had minimal impact on catheter survival. Staphylococcus epidermidis was the most frequently isolated microorganism, and the Palindrome(R) catheter, jugular vein, and being the first vascular access were identified as significant protective factors against tunneled catheter-related bacteremia.

JOURNAL OF NEPHROLOGY (2023)

暂无数据